NKTX → $9.00 by Sep 8, 2026.

NKARTA has become an intriguing speculative investment for me because the company is developing natural killer (NK) cell therapies that could offer advantages over traditional cell therapies in terms of safety, scalability, and accessibility. While many biotechnology companies remain focused on crowded areas of oncology, NKARTA is pursuing a differentiated platform with the potential to address multiple blood cancers and autoimmune diseases. The company's technology is designed to create off-the-shelf treatments that could be manufactured more efficiently than personalized therapies, …